Breast cancer in 2017: Spurring science, marking progress, and influencing history
Breast cancer in 2017: Spurring science, marking progress, and influencing historyBreast cancer in 2017: Spurring science, marking progress, and influencing history, Published online: 12 December 2017; doi:10.1038/nrclinonc.2017.191Data published in 2017 underscore the benefit of optimizing anti-HER2 therapy in early stage high-risk HER2-positive disease, and of capecitabine in patients with residual disease after optimal neoadjuvant therapy. In the advanced-stage setting, endocrine therapy combined with cyclin-dependent kinase 4/6 inhibitors, or olaparib could become the preferred option.
Source: Nature Clinical Practice Oncology - Category: Cancer & Oncology Authors: Jose Perez-Garcia Javier Cortes Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Endocrine Therapy | HER2 | Neoadjuvant Therapy | Science | Xeloda